MGMT and glioblastoma: Our extensive characterisation of potential toxicity through analyses of liver function, bone marrow-derived cells, coagulation profiles and animal weights proved the treatment safe and tolerated, consistent with patient clinical trials.19,21–23 Our results suggest that such a sensitisation schedule may be of clinical benefit for GBM patients with unmethylated MGMT promoter.